CClinicalTrials.gg
CompletedNCT03434288RAPDIAGOSUpdated Jun 5, 2020

Assessment of PCR Multiplex Tests as a Tool to Obtain a Quicker Diagnosis of Bacteria Responsible for Foot Osteomyelitis Than Usual Cultures

An observational study in Diabetes Mellitus and Foot Osteomyelitis, sponsored by University Hospital, Montpellier. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-05.

Sponsored by University Hospital, Montpellier · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
48
Ages
18 Years and older
Sex
All
01

Study summary

Bone samples from infected diabetic feet will be collected and tests will be performed for the diagnosis of causative bacteria. Samples will be processed by PCR multiplex tests and usual cultures for identification of causative bacteria and sensitivity to antibiotics. Results obtained by the two methods will be compared in terms of quickness and similarity of germ identification. Usual care strategy will not be modified since results of PCR multiplex tests will not be transmitted to the physicians before the results of usual cultures.

Read the detailed description

This study will investigate the quickness of identification of bacteria causing bone infection in the feet of patients with diabetes from bone samples obtained by biopsies performed in usaual care practice.

Bone biopsies will be performed in patients diagnosed for osteomyelitis from clinical, biological and MRI signs. Bone samples will be collected in Ultra-Turrax® tubes in the operating theater before being transferred to the department of bacteriology. Time of registration at the bacteriology lab will be considered as Time 0 (T0).

Samples will be processed simultaneously using the usual culture method and by PCR Multiplex tests.

The time of identification of causative bacteria for bone infection (time 1, T1) and the time of identification of sensitivity/resistance to antibiotics (time 2, T2) by the two different methods will be recorded.

Identified germs and their sensitivity/resistance to antibiotics according to the two methods will be compared.

If the results are similar, the time that could be gained for the prescription of specific antibiotics from PCR multiplex tests' results will be computed in comparison to the prescription performed from the results of usual cultures.

02

Conditions studied

  • Diabetes Mellitus
  • Foot Osteomyelitis

Browse trials for

Keywords

  • Diabetes
  • Diabetic foot
  • Osteomyelitis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Diabetic patients admitted in hospital for foot osteomyelitis

Inclusion criteria

  • Biological and MRI signs of foot osteomyelitis
  • Indication of bone biopsy
  • No antibiotics since 2 weeks

Exclusion criteria

Exclusion criteria:

  • Antibiotic therapy
  • Previous cultures for the same infectious event
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
48 participants (actual)
Patient registry
No

Groups and cohorts

  • Diabetic patients with foot osteomyelitis

    Biological and MRI signs of foot osteomyelitis

    Other: Bone sampling

Interventions

  • OtherBone sampling

    Bone biopsy in Diabetic patients with foot osteomyelitis

05

What researchers measure

Primary outcomes

  1. Time for identification of bacteria responsible for foot osteomyelitis

    The difference of time between usual cultures and PCR multiplex tests to identify responsible bacteria will be assessed

    Time frame: 12-48 hours

Secondary outcomes

  1. Time for identification of sensitivity/resistance to antibiotics of the bacteria responsible for foot osteomyelitis

    The difference of time between usual cultures and PCR multiplex tests to identify sensitivity/resistance to antibiotics of responsible bacteria for foot osteomyelitis will be assessed

    Time frame: 12-96 hours

06

Study locations

1 site
  • Uhmontpellier
    Montpellier, 34295, France
07

References and documents

Individual participant data

Plan to share: Undecided — NC

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03434288
Lead sponsor
University Hospital, Montpellier
Responsible party
Sponsor
First posted
Feb 15, 2018
Start date
Feb 8, 2018
Primary completion
Dec 1, 2019
Completion
Dec 1, 2019
Last update
Jun 5, 2020

Study contacts

Eric RENARD, MD, PhD
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion